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During vertebrate embryonic development, a common pool of progenitor cells 
gives rise to all three lineages of the pancreas, including endocrine, exocrine and duct 
cells. The molecular mechanisms regulating pancreatic differentiation are 
incompletely understood. We investigated the function of two genes in the control of 
pancreatic differentiation. In chapter two, we show that Sel1L (Sel-1 suppressor of lin-
12-like) is a potential Notch regulator during pancreas development. SEL1L is initially 
expressed throughout the pancreatic epithelia and later restricted in differentiated cells. 
Mice lacking SEL1L show severe defects in the differentiation of both endocrine and 
exocrine pancreas. These differentiation defects can be rescued by the Notch signaling 
inhibitor, DAPT. In chapter three, we show that RFX6 (Regulatory factor X 6) 
functions as a transcription factor in the developing pancreas. Knockdown of RFX6 in 
zebrafish causes disorganized pancreatic morphology and attenuated insulin 
expression. Expression of Nkx6.1 is down regulated in pancreatic cell line transfected 
with Rfx6 SiRNA. Luciferase reporter studies reveal that RFX6 activates the proximal 
promoter of Nkx6.1. In summary, our studies have provided new insight in the spatial 
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Diabetes is metabolic disease characterized by hyperglycemia and chronic 
organ damage. The substantial increase of diabetes has become one of the greatest 
concerns in human health. In 2008, over 24 million people in the United States were 
diagnosed with diabetes, along with 57 million people estimated to have pre-diabetes 
[1]. Diabetes consists of 2 major types, type 1 and type 2. In type 1, β cells are 
destroyed by autoimmune disorders [2]. In type 2 Diabetes, hyperglycemia is caused 
by insulin resistance in the peripheral organs and the inability of the pancreas to 
compensate via insulin secretion [3].  
Currently daily insulin injection is the only treatment for type 1 diabetes and 
for some cases of severe type 2 diabetes [4, 5]. Islets transplantation has been proven 
to be a promising treatment for type 1 diabetes [6, 7]. However, clinical application of 
islets transplantation is limited by autoimmune response after transplantation and the 
source of islets donors. Potential alternative sources of β cells include differentiated 
embryonic and adult stem cells. Thus a complete understanding of the molecular 
factors regulating β cell formation will greatly facilitate the development of cell-based 
therapies [9, 10, 11].   
 
1.1 Morphogenesis during pancreas development 
 
The pancreas is a bi-functional organ composed of 3 different cells types, 
exocrine cells that excrete digestive enzymes, endocrine cells that secrete peptide 
hormones and the multi-branched pancreatic ducts that channels digestive enzymes. 
The endocrine compartment is organized as the islets of Langerhans, with each islet 
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consisting of five subtypes of cells, α cells that secrete glucagon, β cells that secrete 
insulin, δ cells that secrete somatostatin, PP cells that secrete pancreatic polypeptide 
and ε cells that secrete ghrelin [12, 13, 14].  
Pancreas development in mice starts at approximately e9.0 as a thickening 
patch of epithelial cells from the primitive foregut endoderm. These cells co-express 
Pdx1 and Ptf1a, the earliest and most specific genes that determine a pancreatic fate 
[15, 16]. Later, a second Pdx1/Ptf1a co-expressing domain is defined on the ventral 
side of the primitive foregut [20, 21, 22]. The two pancreatic epithelial domains 
thicken and form an observable dorsal bud at e9.5 and ventral bud at e10.5. Between 
e10.5 to e12.5, the two buds branch out to form a glandular structure with several 
folds increase in size. In the meantime, rotation of the gut brings the ventral bud to the 
dorsal side and the two buds fuse into one interconnected pancreatic bud on e12.5 [23, 
24].  
The endocrine and exocrine cells of the pancreas differentiate asychronically 
during pancreatic development. Scattered endocrine cells appear as early as e9.5. 
These cells express either glucagon or insulin [25, 26]. This event of early endocrine 
cell differentiation is known as the primary transition. Following the primary 
transition, a great number of endocrine cells start to appear in the center of the 
developing pancreas at e13.5, along with amylase expressing cells emerging on the 
peripheral region. This synchronically differentiation of endocrine and exocrine cells 
is known as the secondary transition [27, 28]. It has been suggested that the primary 
and secondary transition are regulated by distinct transcriptional programs [25, 29]. 
Genetic disruption of the essential transcription factor Pdx1 eliminates both pancreas 
development and endocrine cells from the secondary transition, but the endocrine cells 
from the primary transition are not affected [30, 31].  
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Both endocrine and exocrine compartments grow significantly during neonatal 
period in order to meet the physiological demand after birth and weaning [32]. During 
this period, endocrine cells migrate to form islets that scatter throughout exocrine 
tissues. The adult pancreas can expand and regenerate its lost tissue in response to 
pathological and physiological conditions [33, 34].  
 
1.2 Signaling pathways controlling pancreatic development 
 
The Hedgehog pathway signaling controls the initiation and positioning of the 
pancreatic endoderm at early development stages [37]. Hedgehog inhibits early Pdx1 
expression and hence suppresses pancreas formation. During early embryonic 
development, hedgehog is expressed throughout the primitive foregut endoderm but 
inhibited on the pancreatic region, permitting the expression of Pdx1. This critical 
inhibition of hedgehog results from the surrounding environment of the primitive 
foregut endoderm. Previous studies have shown that specification of the dorsal 
pancreatic endoderm is induced by activin signaling from the adjacent notochord [17, 
18, 19]. In the ventral bud, down-regulation of hedgehog is correlated with epithelium 
migration from its originally high levels of FGF and BMP environment, which 
normally stimulate hedgehog signaling [38].  
Endothelial signals from the dorsal aortas are essential for maintaining the 
proliferation of PDX1-positive pancreatic endoderm at early stages. It has been found 
that the endothelial signals also induce Ptf1a, another crucial transcription factor that 
contributes to the determination of pancreatic endoderm. Endothelial signaling also 
contributes to the vascularization in the developing and mature pancreas [39, 40, 41].  
Signals from the surrounding mesenchymal tissue play an important role in the 
morphogenesis and cellular differentiation of the embryonic pancreas. Epithelium 
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separated from its surrounding mesenchyme fails to expand and to differentiate in 
vitro. However, the normal development of the pancreatic epithelium is restored when 
co-cultured with mesenchyme [42]. These evidences suggest that the surrounding 
mesenchyme tissue provides essential signals for pancreas development and 
differentiation.  
Recent studies have revealed that Wnt signaling promotes proliferation while 
suppresses differentiation of the PTF1A-positive cells. In contrast, Wnt signaling has 
little effect on the proliferation and differentiation of the endocrine progenitor cells 
[43].  
FGF family members direct the growth and differentiation of the pancreas. 
Multiple FGF and FGF receptors have been identified in the developing pancreatic 
mesenchyme and epithelium, including FGF1, FGF2, FGF7, FGF9, FGF10 and 
FGF11 [44]. FGF2 promotes the expansion of dorsal pancreatic endoderm [37] while 
suppresses the expansion of ventral pancreatic endoderm [45]. FGF10 is secreted by 
the pancreatic mesenchyme starting from e10.5. Genetic disruption studies of FGF10 
in mice have indicated its role in both inducing PDX1-positive epithelial cells and 
later promoting their rapid proliferation [46, 47]. FGF10 also maintains the 
undifferentiated states of pancreatic progenitor cells. It has been suggested that FGF10 
prevents differentiation through cross-talking with Notch signaling and up-regulating 
the expression of its effector gene Hes1 [48, 49].  
Notch signaling is shown to play a critical role in balancing proliferation and 
differentiation of the multipotent progenitor cells pool. Its detailed function and 





1.3 Transcriptional regulation of pancreas differentiation 
Pdx1 expression starts at e8.5 in the primitive foregut endoderm. The 
expression of Pdx1 later becomes restricted in the central region of the epithelium, 
which later adopts an endocrine fate. In the adult pancreas, Pdx1 is exclusively 
expressed in the islets [31]. Previous studies on insulin transcriptional regulation have 
revealed that PDX1 directly binds to the insulin proximal promoter and activates its 
transcription [54].  
Genetic disruption of Pdx1 causes pancreas agenesis, indicating an essential 
role in pancreas development. However, the presence of a small number of endocrine 
cells in intestine of the PDX1-null mice suggests that an alternative endocrine lineage 
exists independent from Pdx1 induction [55].  
Ptf1a, or p48, is a subunit in the heterooligomeric transcription complex PTF1 
that regulates the expression of a large number of genes in the exocrine pancreas. 
Ptf1a expression is confined in a subset of the Pdx1 expressing cells at e9.5. Ptf1a 
expression becomes progressively exclusive in the periphery of the branching 
pancreatic epithelium that commits to exocrine fate. Knockout of Ptf1a causes major 
defects in pancreas development and only pancreatic remnants can be observed after 
birth [56].  
Both Pdx1 and Ptf1a play fundamental roles in pancreas development. It has 
been generally accepted that the pancreatic endoderm is defined by the overlapping 
expression domains of the two transcription factors. Double knockout of Pdx1 and 
Ptf1a have revealed that Pdx1 is required in a stage prior to Ptf1a in specification of 
pancreatic epithelia. In addition, Pdx1 is required for sustaining the transient 
expression of Ngn3 from e9.5 and thus is essential for defining the endocrine lineage 
in the second transition. In contrast, Ptf1a displays only limited influences on the 
differentiation of endocrine cells [57].  
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Ngn3 functions as a master switch for determining an endocrine cell fate. 
Genetic ablation of NGN3 completely devoids all endocrine cell types. During 
development, expression of Ngn3 is transiently detected in the pancreatic epithelia 
from e9.5. Its expression progressively increases and peaks at e15.5 within the cells 
expressing higher level of Pdx1. Later, Ngn3 expression declines rapidly and becomes 
undetectable after birth. During its transient expression, Ngn3 activates a series of 
downstream transcription factors that are required for the differentiation of endocrine 
cells [58, 59].  
NeuroD1 was identified as a direct target for Ngn3. The expression of 
NeuroD1 starts in all pancreatic endocrine cells including endocrine precursors from 
e9.5. NeuroD1 knock-out mice display severe defects in pancreatic development 
characterized by disorganized islets [60]. IA-1 is another target activated by the 
transcription factor Ngn3. Genetic disruption of IA-1 causes severe impairment of β 
cells differentiation. IA-1-null pancreas accumulates of endocrine precursor cells 
without hormone expression, suggesting that IA-1 might play a role in endocrine cell 
maturation [61].  
Several transcription factors regulate beta cell differentiation and maturation. 
Nkx6.1 has been indentified as a transcription repressor that promotes β cell 
differentiation. Gene targeting of Nkx6.1 in mice causes significant reduction of islets. 
In vitro studies have shown that Nkx6.1 is essential for promoting β cell differentiation 
and survival after the secondary transition [62]. MafA directly activates insulin 
promoter similar to Pdx1. Its expression starts in the primitive insulin-positive cells 
and continues in the mature islets. MafA knockout animals have normal pancreas with 
no significantly reduced β cell number or insulin expression. However, newborns 
rapidly develop impaired glucose tolerance with defects in insulin secretion, 
suggesting its role in beta cell maturation [63].  
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RFX3 is a member of the regulatory factor X family. Analysis of Rfx3 
knockout mice reveals Rfx3 is required for β cell maturation. Furthermore, Rfx3 has 
been shown to directly activate the transcription of glucokinase, a β cell specific 
glucose sensory protein involved in insulin secretion [64, 65].  
 
 
1.4 The Regulation of Pancreatic Progenitor Cells Differentiation by Notch 
Signaling 
 
Notch signaling has been shown to play a critical role in regulating 
proliferation and differentiation of the multipotent progenitor cells pool. Multiple 
Notch family members, including Notch 1-4 and the membrane bound ligands, DLL1, 
DLL3, Jagged 1, Jagged 3, Serrate 1 and Serrate 2 are expressed in the developing 
pancreatic epithelium and mesenchyme [19]. The Notch effector gene, Hes1, inhibits 
the transcription of Ngn3, a crucial transcription factor determining endocrine cell fate 
[50]. During early pancreas development, activated Notch signaling promotes 
proliferation of pancreatic progenitor cells by suppressing both endocrine and exocrine 
cell differentiation. Down-regulation of Notch signaling permits exocrine and 
endocrine cell fate commitment. Transgenic overexpression of notch intracellular 
domain (NICD) attunes both endocrine and exocrine cell differentiation [51, 52]. In 
contrast, genetic inhibition of notch causes premature pancreas [53].  
During pancreas development, the interaction between the membrane bound 
ligand Delta or Serrate and the receptor notch determines binary cell fate through a 
process known as lateral inhibition [66, 67]. In pancreatic progenitor cells, activated 
notch receptor is cleaved and its intracellular domain, NICD, is released. NICD 
translocates into the nucleus and activates the Notch effector gene Hes1 [68]. As a 
  8
transcription repressor, HES1 prevents endocrine cell differentiation by inhibiting the 
transcription of Ngn3. In addition, HES1 directly inhibits p57, a cyclin dependant 
kinase inhibitor that sustains cell cycle arrest [69, 70]. Notch signaling thus inhibits 
differentiation and maintains proliferation of the progenitor cells pool. Notch signaling 
is also modulated by other factors through their regulation of NICD and Hes1 [71, 72, 
73].  
Recently, other transcription factors, including Onecut 1, Foxa2, Tcf2 and Sox9, 
have also been indentified to be important for sustaining progenitor cells pool [74, 75, 
76, 77]. Sox9, a transcription factor highly expressed in the pancreatic multi-potent 
progenitor cells is shown to be the transcription factor that governs this network by 
coordinately activating Onecut 1, Foxa2 and Tcf2. In addition, Sox9 potentially 




In chapter two, the objective was to investigate the regulation of Notch 
signaling in the developing pancreas. Sel1L, suppressor enhancer of lin-12 like, is a 
mammalian homolog of Sel-1 in C.elegans. Sel1L was first identified as a Notch 
repressor in C.elegans [81]. In mice, Sel1L is first expressed at e9.5 in the specified 
pancreatic buds [82, 83]. It has been hypothesized that Sel1L acts as a Notch repressor 
during pancreatic development. We studied the function of Sel1L using a gene-trap 
mice model where Sel1L was truncated in the fourteenth intron by the β-geo cassette. 
In the heterozygous mice line, the Sel1L expressing cell lineage can thus be traced by 
the expression of β-geo. Studies on the pancreas development of the Sel1L 
homozygous mutant were performed to unravel its function during endocrine and 
exocrine cell differentiation. Finally, Notch inhibitor DAPT was used in the mutant 
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explants culture to confirm the relationship between Notch activity and Sel1L 
deficiency.  
In chapter three, the objective was to testify the function of RFX6 in 
controlling β cell differentiation. RFX6 belongs to the Regulatory Factor X family that 
attracted great attention in recent pancreatic development studies [84]. Our previous 
gene differential expression studies have revealed its exclusive expression in the 
developing pancreatic epithelium and in the adult islets. These evidences led to the 
hypothesis that Rfx6 is a novel transcription factor involved in controlling 
differentiation of β cells. We first used zebrafish as a genetic model to study the 
function of RFX6 in pancreas development. In addition, we attempt to identify the 
possible transcription factors that are regulated by Rfx6 in order to place it in the 
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CHAPTER 2 
SEL1L DEFICIENCY IMPAIRS GROWTH AND DIFFERENTIATION OF 
PANCREATIC EPITHELIAL CELLS* 
 
2.1 Abstract 
Background: The vertebrate pancreas contains islet, acinar and ductal cells. 
These cells derive from a transient pool of multipotent pancreatic progenitors during 
embryonic development. Insight into the genetic determinants regulating pancreatic 
organogenesis will help the development of cell-based therapies for the treatment of 
diabetes mellitus. Suppressor enhancer lin12/Notch 1 like (Sel1l) encodes a 
cytoplasmic protein that is highly expressed in the developing mouse pancreas. 
However, the morphological and molecular events regulated by Sel1l remain elusive. 
Results: We have characterized the pancreatic phenotype of mice carrying a 
gene trap mutation in Sel1l. We show that Sel1l expression in the developing pancreas 
coincides with differentiation of the endocrine and exocrine lineages. Mice 
homozygous for the gene trap mutation die prenatally and display an impaired 
pancreatic epithelial morphology and cell differentiation. The pancreatic epithelial 
cells of Sel1l mutant embryos are confined to the progenitor cell state throughout the 
secondary transition. Pharmacological inhibition of Notch signaling partially rescues 
the pancreatic phenotype of Sel1l mutant embryos. 
Conclusions: Together, these data suggest that Sel1l is essential for the growth 
and differentiation of endoderm-derived pancreatic epithelial cells during mouse 
embryonic development. 
 
* Li S, Francisco AB, Munroe RJ, Schimenti JC, Long Q. SEL1L deficiency impairs 
growth and differentiation of pancreatic epithelial cells. BMC Dev Biol. 10:19 2010
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2.2 Background 
The multiple cell types that make up the adult pancreas, including endocrine, 
exocrine and ductal cells, derive from a common pool of pancreatic progenitors. 
Pancreatic development in mice begins at embryonic day 9.5 (E9.5) with the 
formation of two epithelial buds on the dorsal and ventral side of the primitive gut 
endoderm [1]. Epithelial cells within the pancreatic buds proliferate rapidly and 
branch out during later embryonic days to form a complex tubular network comprised 
of undifferentiated multipotent progenitor cells [2, 3]. Starting at E13.5, the expanded 
pancreatic epithelial cells undergo an asynchronized wave of differentiation to give 
rise to all the differentiated cell types of the adult pancreas, including acinar cells that 
produce hydrolytic digestive enzymes and islet cells that secrete endocrine hormones 
[4, 5]. Pancreatic morphogenesis depends on a complex and yet incompletely 
characterized network of transcription factors. Significant efforts have been made in 
the past few years to understand the role of several important transcription factors, 
including Pdx1 [6, 7], Ptf1a [8, 9], Sox9 [10, 11], Ngn3 [12, 13], NeuroD1 [14, 15], 
Pax4 [16], Pax6 [17], Nkx2.2 [18], Nkx6.1 [19], Arx [20], Isl1 [21] and Insm1 [22]. It 
is generally accepted that these transcription factors coordinate pancreatic 
morphogenesis by functioning in concert to restrict the developmental potentials of the 
pancreatic progenitors in a spatial and stage-specific manner [23].  
Several previous studies have underscored the importance of Notch-mediated 
signaling in regulating pancreatic cell proliferation and cell fate decisions through 
control of Ngn3 gene expression. During pancreatic development, Ngn3 is transiently 
expressed in a subset of the pancreatic epithelial cells. NGN3 deficiency completely 
abolishes formation of all the endocrine cell subtypes, suggesting Ngn3 functions as a 
master switch for the endocrine lineage in the pancreas. Mutations in genes encoding 
Notch signaling pathway components, such as DLL1 (ligand), RBP-Jk (the 
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intracellular mediator), or HES-1 (the effector) causes expansion of Ngn3 expression 
in pancreatic cells and, as a result, accelerated differentiation of endocrine cells at the 
expense of acinar and ductal cells [13, 24, 25]. Conversely, over or persistent 
expression of the Notch intracellular domain (NICD), a constitutively active form of 
Notch receptors, or the Notch effector gene Hes1 results in diminished expression of 
Ngn3 and attenuated differentiation of endocrine cells [26-28]. These studies suggest 
that during pancreatic development Notch signaling controls the endocrine and 
exocrine cell fate decisions of pancreatic epithelial cells by directly regulating Ngn3 
expression. Recent studies have also indicated the importance of Notch signaling in 
control of exocrine cell differentiation. Ectopic expression of activated NOTCH-1 
prevents or significantly delays differentiation of acinar cells [26, 27].  
While the role of Notch signaling in control of pancreatic cell proliferation and 
cell fate decisions is clearly recognized, the molecular mechanisms necessary for 
proper control of Notch signaling during vertebrate pancreatic development are poorly 
understood. Genetic and biochemical studies in invertebrates suggest that regulation of 
Notch signaling occurs at various levels and through multiple mechanisms [29, 30, 31]. 
These include stochastic and/or developmental expression of the Notch receptors and 
their ligands [32, 33, 34], selective receptor-ligand interactions [35, 36], intracellular 
protein trafficking [37] and stability of NICD [38]. Suppressor enhancer lin12 1 like 
(Sel1l) encodes a cytoplasmic protein that is highly conserved throughout the 
vertebrate kingdom [39]. RNA in situ hybridization and immunohistological analysis 
revealed that Sel1l is highly expressed in both the embryonic and adult pancreas [40, 
41, 42]. The human Sel1l gene is located in a chromosome region that is in close 
proximity to a type 1 diabetes high risk locus, IDDM-11 (insulin-dependent diabetes 
mellitus locus 11), prompting the speculation that mutations in Sel1l may be 
associated with the pathogenesis of type 1 diabetes [43]. Sel-1, the C. elegans ortholog 
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of Sel1l, was first identified in a genetic screen for mutations that suppress lin-
12/Notch activity [44]. Subsequent biochemical studies demonstrated that Sel-1 
negatively regulates lin-12/Notch activity by controlling lin-12/Notch turn-over [45, 
46]. Based on these findings, it has been suggested that Sel1l may also function as a 
negative regulator for Notch signaling [47]. Recent biochemical and molecular studies 
in vitro revealed that Sel1l is also required for maintaining homeostasis of the 
endoplasmic reticulum (ER). SEL1L nucleates an ER membrane protein complex that 
is required for dislocation of unfolded or misfolded proteins from the ER lumen into 
the cytosol for degradation [48, 49]. 
In an attempt to decipher the developmental and physiological roles of Sel1l, 
we have generated and characterized mice carrying a gene trap mutation in the Sel1l 
gene. We report here that Sel1l expression during pancreas development coincides 
with differentiation of pancreatic epithelial cells into both the endocrine and exocrine 
lineages. Homozygous Sel1l mutant embryos exhibit an impaired pancreatic epithelial 
growth and branching morphology. Pharmacological inhibition of Notch signaling 
rescues the pancreatic phenotype of Sel1l-deficient embryos. These data are consistent 
with the notion that Sel1l functions as a negative regulator for Notch signaling during 
pancreatic organogenesis [47]. 
 
2.3 Results 
Sel1l expression during mouse pancreatic development 
We generated mice carrying a gene-trap insertion in the Sel1l gene. The gene 
trap cassette, located in intron 14, contains a β-galactosidase-neomycin (βgeo) fusion 
reporter gene. To determine the spatiotemporal expression pattern of Sel1l in the 
developing mouse pancreas, we performed immunohistological analysis of pancreatic 
sections from Sel1l+/βgeo embryos using antibodies against β-galactosidase (βgal) and 
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several pancreatic proteins, including SOX9 and PDX1 (progenitor markers), insulin 
and glucagon (endocrine lineage markers) and amylase (exocrine lineage marker). 
βgal expression was first detected at E12.5 in a small number of cells located within 
the core of SOX9-expressing pancreatic epithelium (Fig. 2.1A-B). The βgal+ cells at 
E12.5 express either glucagon (Fig. 2.1C) or insulin (Fig. 2.1D), indicating that they 
were early endocrine cells. βgal expression expands significantly between E12.5 and 
E14.5. At E14.5, differential βgal expression was detected in the PDX1+ cells 
throughout the pancreatic epithelium (Fig. 2.1E). Epithelial cells with markedly lower 
βgal expression correspond to a subset of PDX1+ cells that express SOX9 (Fig. 2.1F). 
At E15.5, high βgal expression was detected in the core of the differentiating pancreas 
(Fig. 2.1G-H, asterisks). These βgal+ cells were positive either for glucagon or insulin 
(arrows in Fig. 2.1I and Fig. 2.1J respectively). At birth, βgal expression was detected 
in both islet and acinar cells (Fig. 2.1K-L, asterisk and arrow, respectively). Taken 
together, these expression data indicate that Sel1l is selectively expressed in the 
differentiating or differentiated pancreatic epithelial cells.  
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Figure 2.1 Spatiotemporal expression of Sel1l during development of the mouse 
pancreas. Pancreatic sections from timed Sel1l+/βgeo embryos were co-immunostained 
with antibodies against βGal (red) and various pancreatic markers (green) as indicated 
on the left side of each panel. (B and H) Magnified views of the boxed area in A and 
G, respectively. (A-D) βGal expression at E12.5. βGal expression begins in a small 
number of cells within the core pancreatic epithelium at E12.5 (A). At this stage, there 
is no co-expression of βGal and SOX9 (B); however, βGal is co-expressed with either 
glucagon (C) or insulin (D). (E-F) βGal expression at E14.5. βGal is differentially 
expressed in the PDX1+ cells (E). While high βGal signal was detected in the 
epithelial branches (arrows), no or very low βGal signal was detected in the core 
"duct-like" epithelium (arrowhead). These core epithelial cells correspond to the 
subset of PDX+ cells that express SOX9 (F). (G-J) βGal expression at E15.5. βGal 
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expression increases markedly in the core pancreatic epithelium (G and H, asterisks). 
βGal co-localizes with either glucagon (I, arrows) or insulin (J, arrows). (K-L) βGal 
expression at postnatal day 1. βGal is expressed in both islet and acinar tissues (K, 
asterisk and arrow, respectively). βGal co-localizes with PDX1 in the islet tissue (L). 
Scale bars: (A, G, I and J) 50 μm; (B-F, K-L) 100 μm. 
 
SEL1L deficiency results in defective pancreatic epithelial growth and branching 
morphogenesis 
The gene trap in Sel1l contains a strong splicing acceptor signal that efficiently 
blocks splicing between exon 14 and 15, resulting in a truncated Sel1l transcript. 
Homozygous gene trap mice (Sel1lβge/βgeo) exhibit systemic endoplasmic reticulum 
stress and die before E13.5 to E15.5 (Fig. 2.7). To determine if Sel1l is required for 
pancreatic epithelial growth, we performed morphometrical analysis of the developing 
pancreas of viable Sel1lβgeo/βgeo embryos. At E11.5, the dorsal and ventral pancreatic 
buds in Sel1lβgeo/βgeo embryos appeared to be closely linked (Fig. 2.2B), as compared to 
those in wild-type embryos (Fig. 2.2A). There was no significant difference in the 
pancreatic epithelial size between wild-type and Sel1lβgeo/βgeo embryos (Fig. 2.2E). At 
E13.5, the dorsal pancreatic bud of Sel1lβgeo/βgeo embryos (Fig. 2.2C) was clearly 
smaller than that of wild-type embryos (Fig. 2.2F). In addition, while wild-type 
pancreatic epithelium displayed a well-branched structure, mutant pancreatic 
epithelium appeared to be a simple tube of epithelial cells. TUNEL assays revealed no 
significant increase of apoptosis in the developing pancreas of Sel1l mutant embryos 
(data not shown). Immunostaining using anti-PCNA (a cell proliferation indicator) 
antibody indicated that the pancreatic epithelium of Sel1l mutant embryos had a 
significantly lower rate of cell proliferation than wild-type pancreatic epithelium (Fig. 
2.2G). Together, these results indicate that Sel1l, while dispensable for pancreatic 
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epithelial induction, is essential for the subsequent growth and branching 
morphogenesis of the pancreatic epithelial cells. 
 
 
Figure 2.7 Characterization of the gene trap allele in Sel1l. (A) Schematic 
representation of the wild-type (Sel1l+) and gene trap (Sel1lβgeo) allele in Sel1l. Solid 
black rectangles represent exons; the open box in the Sel1l- allele represents the gene 
trap insertion. Splicing events are indicated by dashed lines. (B) PCR analysis of 
genomic DNAs from wild-type (WT), heterozygous (HT) and mutant (MU) mice 
using the indicated Sel1l and βgeo-specific primers (arrows). The data confirm the 
presence of a gene trap insertion in intron 14. (C) RT-PCR analysis of RNAs from 
E12.5 WT, HT and MU embryos using the indicated Sel1l and βgeo-specific primers 
(arrows). The data indicate that the gene trap allele in Sel1l completely blocks RNA 
splicing between exon 14 and 15, resulting in a truncated Sel1l transcript fused in 
frame with βgeo transcript. (D) Schematic representation of the full-length (FL) (top) 
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and deletion mutant (DM) SEL1L peptides generated from the wild-type and gene trap 
Sel1l alleles. Key protein domains are shown in colored boxes. Numbers represent 
amino acid positions. The gene trap allele in Sel1l generates a fusion protein 
containing the N-terminal 465 amino acids of SEL1L and βgeo. The mutant peptide 
lacks the Hrd3-like motif, the transmembrane domain, the proline-rich domain and 4 
SEL1L-like repeats.  
 
 
Figure 2.2 Impaired pancreatic epithelial growth and branching morphogenesis 
in Sel1lβgeo/βgeo embryos. (A-D) Immunohistological analysis of the developing 
pancreas of wild-type and Sel1lβgeo/βgeo embryos at E11.5 and E13.5; the genotypes of 
the pancreatic sections are indicated as +/+ and -/-, respectively. The following 
antibodies were used: Pdx1 (A-D, green) and insulin (C-D, red). (A-B) The dorsal and 
ventral pancreatic buds in Sel1lβgeo/βgeo embryos are fused together. (C-D) The dorsal 
pancreatic bud of Sel1lβgeo/βgeo embryos exhibits a markedly reduced epithelial size and 
an impaired branching morphology. (E-F) Statistical analyses of estimated pancreatic 
epithelial sizes of wild-type and Sel1lβgeo/βgeo embryos at E11.5 (E) and E13.5 (F). 
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Data were from three sets of wild-type and Sel1lβgeo/βgeo embryos. No significant 
difference in the epithelial sizes of wild-type and Sel1l-deficient pancreas at E11.5 
was detected (E). At E13.5, the pancreatic epithelium of Sel1l-deficient embryos was 
significantly smaller (F). Scale bar: 100 μm. 
 
SEL1L deficiency inhibits differentiation of acinar cells and significantly 
attenuates differentiation of endocrine cells 
We next investigated the role of Sel1l in pancreatic epithelial cell 
differentiation. Since the first wave of cell differentiation occurs before E12.5 and the 
cells generated are mostly α-cells, we analyzed glucagon expression in E11.5 
Sel1lβgeo/βgeo embryos. As shown in Fig. 2.3A-B and 2.3G, comparable numbers of 
glucagon+ cells were observed in wild-type and Sel1lβgeo/βgeo embryos. Sel1l is thus 
unlikely to be required for the generation of early endocrine cells during the first 
transition (E9.5 to E12.5). 
While the majority of Sel1lβgeo/βgeo embryos (95%) die before the initiation of 
the major wave of cell differentiation in the developing pancreas (E13.5), about 5% of 
these embryos are viable at E15.5. To determine if Sel1l is required for differentiation 
of pancreatic epithelial cells during the secondary transition (E13.5 to E15.5), we 
analyzed the expression of three pancreatic lineage markers: insulin (β-cells), 
glucagon (α-cells) and amylase (acinar cells) in these embryos. Significant numbers of 
glucagon+ and insulin+ cells were detected in wild-type embryos at E15.5 (Fig. 2.3C 
and 2.3E). In contrast, the numbers of glucagon+ and insulin+ cells were significantly 
reduced in Sel1lβgeo/βgeo embryos (Fig. 2.3D and 2.3F, 2.3H and 2.3I). Abundant 
amylase+ cells are present in wild-type embryos at E15.5 (Fig. 2.4E). In contrast, no 
amylase+ cells are detectable in Sel1lβgeo/βgeo embryos (Fig. 2.4F). Disruption of Sel1l 




Figure 2.3 Inhibited endocrine and exocrine cell differentiation in Sel1lβgeo/βgeo 
embryos. (A-F) Immunohistological analysis of the developing pancreas of Sel1l+/+ 
and Sel1lβgeo/βgeo embryos at E11.5 (A-B) and E15.5 (C-F); the genotypes of the 
pancreatic sections are indicated as "+/+" and "-/-", respectively. The following 
antibodies were used: Pdx1 (A-D, green), glucagon (A-D, red), insulin (E-F, red) and 
amylase (E-F, green). (A-B) At E11.5, Glu+ cells were detected in the pancreatic 
epithelium of wild-type and Sel1lβgeo/βgeo embryos in equal numbers. (C-D) At E15.5, 
the number of glucagon+ cells was reduced in Sel1lβgeo/βgeo embryos as compared to 
wild-type control. (E-F) No amylase+ cells were detected and the number of insulin+ 
cells was significantly reduced in Sel1lβgeo/βgeo embryos. (G-I) Statistical analyses of 
the numbers of glucagon+ and insulin+ cells in wild-type and Sel1lβgeo/βgeo embryos. 
Data were from three wild-type and three Sel1lβgeo/βgeo embryos. At E11.5, no 
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significant difference in the number of glucagon+ cells in wild-type and Sel1lβgeo/βgeo 
embryos was detected (G). The number of glucagon+ and insulin+ cells was markedly 
lower in Sel1lβgeo/βgeo embryos than in wild-type control embryos (H and I, 
respectively). Scale bar: 100 μm. 
 
SEL1L-deficient pancreatic epithelium exhibits inhibited growth and 
differentiation ex vivo 
To ensure that the growth and differentiation defects observed in Sel1lβgeo/βgeo 
embryos were not due to the effect of global embryonic growth retardation of these 
embryos, we studied the pancreatic phenotype of Sel1lβgeo/βgeo embryos using an organ 
culture system. The dorsal pancreatic bud of wild-type and Sel1lβgeo/βgeo embryos were 
isolated at E11.5 and cultured for 8 days. The cultured pancreatic explants were then 
analyzed by immunofluorescence using antibodies against PDX1 and insulin. In 
general, Sel1l-deficient pancreatic epithelium grows poorly (Fig. 2.8B and 2.8D) with 
about half of the cultured mutant epithelia failing to form branched epithelial 
structures. This is in sharp contrast to the growth behavior of wild-type pancreatic 
epithelia, which form a branched epithelial structure (Fig. 2.8). The number of insulin+ 
cells was significantly decreased in Sel1l-deficient pancreatic explants (Fig. 2.4B), as 
compared to that in wild-type control explants (Fig. 2.4A). Amylase+ cells were 
detected in cultured Sel1l-deficient explants (Fig. 2.4D), although the number of 
amylase+ cells was significantly lower compared to that in wild-type control explants 
(Fig. 2.4C). Thus, the pancreatic epithelium of Sel1lβgeo/βgeo embryos displays impaired 
growth, branching morphogenesis and lineage differentiation ex vivo. These findings 
confirm that the pancreatic defects observed in Sel1l-deficient embryos at E15.5 are 




Figure 2.8 Sel1l-deficient pancreatic epithelium exhibits impaired growth, 
branching morphology and differentiation ex vivo. The dorsal pancreatic bud of 
wild-type (+/+) and Sel1lβgeo/βgeo (-/-) embryos were isolated at E11.5 and cultured as 
described in Materials and Methods. Cultured pancreatic explants were 
immunostained with the indicated antibodies. Sel1l-deficient pancreatic epithelium 
grows poorly and displays impaired branching morphology (B and D), as compared to 
wild-type control explants (A and C). Scale bar: 100 μm. 
 
 
Figure 2.4 Sel1l-deficient pancreatic epithelium exhibits impaired growth, 
branching morphology and differentiation ex vivo. Dorsal pancreatic buds of wild-
type and Sel1lβgeo/βgeo embryos were isolated at E11.5 and cultured as described in 
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Materials and Methods. The genotypes of the pancreatic explants are indicated as 
"+/+" and "-/-", respectively. Cultured pancreatic explants were immunostained using 
the indicated antibodies. Sel1l-deficient pancreatic epithelium grows poorly and 
displays impaired branching morphology (B and D), as compared to wild-type control 
explants (A and C). The number of insulin+ cells in mutant pancreatic epithelia were 
markedly reduced (B, arrows), as compared to the wild-type controls (A, arrows). 
Amylase expression was detected in Sel1l-deficient pancreatic epithelium (D, arrows), 
but the expression is significantly lower than that in wild-type epithelium (C, arrows). 
Scale bar: 100 μm. 
 
Pancreatic progenitor cells in SEL1L-deficient embryos at E15.5 are confined to 
a pluripotent progenitor state 
To gain insight into the molecular basis underlying the pancreatic defects in 
Sel1lβgeo/βgeo embryos, we first analyzed the expression of several transcription factors 
important for pancreatic epithelial growth and lineage formation. Immunostaining was 
carried out to assess the expression of Sox9, Pdx1 and Ptf1a in E15.5 Sel1lβgeo/βgeo 
embryos. PDX1 expression was uniformly detected in the pancreatic epithelial cells of 
Sel1lβgeo/βgeo embryos (Fig. 2.5B). This is in sharp contrast to wild-type embryos where 
PDX1 expression was differentially expressed in the pancreatic epithelial cells, with 
high expression in a subset of the core epithelial cells and low expression in the 
peripheral epithelial cells (Fig. 2.5A, white arrow and red arrowheads, respectively). 
No PTF1a expression was detected in the pancreatic epithelium of Sel1lβgeo/βgeo 
embryos (Fig. 2.5B), whereas clear co-expression of PTF1a and PDX1 was detected in 
the proacini in the periphery of the pancreatic epithelial buds (Fig. 2.5A, white arrows). 
SOX9 was detected in approximately 20% of the PDX1+ cells in wild-type embryos 
(Fig. 2.5C, red arrows). In contrast, SOX9 expression was observed in more than 70% 
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of the PDX1+ cells in Sel1lβgeo/βgeo embryos (Fig. 2.5D, asterisk). These findings are 
consistent with the notion that the pancreatic epithelial cells in Sel1lβgeo/βgeo embryos at 
E15.5 are restricted the pancreatic progenitor state.  
 
 
Figure 2.5 Sel1l-deficient pancreatic epithelial cells fail to commit to lineage 
precursors during the secondary transition. (A-D) Immunohistological analysis of 
the developing dorsal pancreas of wild-type and Sel1lβgeo/βgeo embryos at E15, using 
the indicated antibodies. The genotypes of the pancreatic sections are indicated as 
"+/+" and "-/-", respectively. (A-B) PTF1a is expressed in the periphery of wild-type 
pancreatic epithelium marking the commitment of pancreatic epithelial cells into the 
exocrine lineage (A, white arrows); PTF1a expression is absent in the mutant pancreas 
(B). Up-regulation of PDX1 expression in a subset of epithelial cells in the core of 
wild-type pancreatic epithelium marks the commitment of pancreatic epithelial cells 
into the endocrine lineage (A, red arrows); whereas PDX1 is uniformly expressed in 
mutant pancreatic epithelial cells (B). (C-D) SOX9 is expressed in a small population 
of epithelial cells in wild-type pancreatic epithelium (C, red arrows); in contrast, 
SOX9 mostly co-localizes with PDX1 in mutant pancreatic epithelium (D, asterisks). 
Scale bar: 100 μm. 
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Pharmacological inhibition of Notch signaling rescues endocrine lineage 
formation in Sel1lβgeo/βgeo embryos 
Sel1l was thought to be a negative regulator for Notch signaling [47]. Indeed, 
the pancreatic phenotype in Sel1lβgeo/βgeo embryos shows remarkable similarity to that 
of mouse or zebrafish embryos over-expressing Notch intracellular domain, the 
constitutively active form of Notch receptors [26, 28, 50]. We speculated that the 
impaired pancreatic epithelial growth and differentiation in Sel1l-deficient embryos 
may be due to an increased Notch signaling activity. To test this possibility, we used 
the γ-secretase inhibitor, DAPT (Difluorophenacetyl-al-alanyl-S-phenylglycine-t-butyl 
ester), to suppress Notch signaling in pancreatic explants culture. The dorsal 
pancreatic bud of wild-type and Sel1lβgeo/βgeo embryos was isolated at E11.5 and 
cultured for 8 days in the absence or presence of DAPT. At a concentration of 10 μM, 
DAPT did not exhibit detectable effects on the growth, branching morphology and 
endocrine cell differentiation of wild-type pancreatic epithelium (Fig. 2.6A-B and 
2.6E). At the same concentration, however, DAPT caused a significant expansion of 
the SEL1L-deficient pancreatic epithelium (Fig. 2.6C-D). Importantly, DAPT 
treatment resulted in a marked increase in the number of insulin+ cells (Fig. 2.6D and 
2.6F). These observations indicate that pharmacological inhibition of Notch signaling 
rescues, at least partially, the pancreatic epithelial growth and endocrine 




Figure 2.6 DAPT treatment rescues the pancreatic phenotype of Sel1lβgeo/βgeo 
embryos. The dorsal pancreatic bud of wild-type (+/+) and Sel1l mutant (-/-) embryos 
was isolated at E11.5 and cultured for 8 days in the presence of 0.1% DMSO (control) 
and 10 μM of DAPT. (A-D) Immunohistological analysis of DAPT-treated and non-
treated pancreatic buds with the indicated antibodies. (E-F) Quantification of insulin+ 
cells in DMSO and DAPT-treated pancreatic explants. DAPT did not significantly 
change the number of insulin+ cells in wild-type pancreatic buds (A-B and E), however, 
it induced a marked increase of insulin+ cells in Sel1l mutant pancreatic buds (C-D and 
F). Scale bar: 100 μm.  
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2.4 Discussion 
The genetic determinants underlying vertebrate pancreatic development are not 
completely understood. In the present study, we report that Sel1l expression in the 
developing mouse pancreas coincides with differentiation of the endocrine and 
exocrine lineages during the second transition. Embryos homozygous for a gene trap 
insertion in Sel1l display impaired pancreatic epithelial growth and differentiation. 
Pharmacological inhibition of Notch signaling partially rescues the pancreatic 
phenotype of SEL1L-deficient embryos. Together, these data provide evidence that 
Sel1l is required for growth and differentiation of the mammalian pancreatic epithelial 
cells. The underlying mechanism may be that Sel1l functions as a negative regulator 
for the Notch signaling pathway by facilitating degradation of the Notch intracellular 
domain. 
Donoviel et. al. previously reported that the mouse Sel1l gene is highly 
transcribed in the acini of the developing pancreas at E14.5 and E17.5 [41]. We show, 
by immunohistological analysis of the β-galactosidase reporter in Sel1l, that Sel1l is 
also highly expressed in early glucagon+ and insulin+ cells (Fig. 2.1C and 2.1D, 
respectively) generated during the first transition period of pancreatic development [5, 
51, 52]. Consistent with the Sel1l mRNA expression pattern reported by Donoviel et. 
al., we reveal that at E14.5 Sel1l is broadly expressed in the PDX1+ pancreatic 
epithelia (Fig. 2.1E). Interestingly, significantly lower Sel1l expression is observed in 
the undifferentiated pancreatic epithelial cells (Fig. 2.1F) that express SOX9 [10, 11]. 
Our findings therefore indicate that Sel1l expression is enhanced in the committed 
pancreatic epithelial cells or differentiated endocrine and exocrine cells. 
The selective expression of Sel1l in differentiating or differentiated pancreatic 
epithelial cells is highly suggestive of a role for Sel1l in promoting lineage 
differentiation during the secondary transition. To define the role of Sel1l in pancreatic 
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development, we characterized the pancreatic phenotype of embryos homozygous for 
a gene trap insertion in Sel1l. We show that wild-type and Sel1l-deficient embryos 
have a comparable pancreatic epithelial size at E11.5 (Fig. 2.2A-B and 2.2E), 
suggesting that Sel1l function is dispensable for the induction and early growth of 
pancreatic epithelial cells. At E13.5, however, Sel1l-deficient pancreatic epithelia are 
significantly smaller and display an impaired branching morphology (Fig. 2.2C-D and 
2.2F). Importantly, Sel1l-deficient pancreatic epithelia at E15.5 completely lack 
amylase+ cells (Fig. 2.3F) and have significantly reduced numbers of glucagon+ and 
insulin+ cells (Fig. 2.3D and 2.3F, respectively). Also, by analyzing the phenotype of 
cultured Sel1l-deficient dorsal pancreatic epithelia, we confirmed that the pancreatic 
defects in Sel1l-deficient embryos are not due to the effect of global growth 
retardation of the Sel1l-deficient embryos (Fig. 2.4A-D). Together, these data strongly 
suggest that Sel1l plays an important role in mouse pancreatic organogenesis by 
facilitating differentiation of the endocrine and exocrine lineages of the pancreas. 
The C. elegans ortholog of the mammalian Sel1l gene, Sel-1, was originally 
identified by genetic screening as a negative regulator for lin-12/Notch signaling [44, 
53]. Biochemical studies have shown that Sel-1 regulates lin-12/Notch receptor 
turnover [45, 46]. Whether or not Sel1l has similar functions in the mammalian system 
remains unclear [54]. In this study, we provide two lines of evidence that suggest Sel1l 
also functions as a negative regulator for Notch signaling, at least in the developing 
mouse pancreas. First, the observed pancreatic phenotype in Sel1l mutant embryos 
show remarkable similarity to the pancreatic phenotype of transgenic vertebrate 
embryos over-expressing the Notch intracellular domain, the constitutively active 
form of Notch [26, 28, 50]. Second, we show that treatment of cultured Sel1l-deficient 
pancreatic epithelium with DAPT, a potent Notch signaling inhibitor, partially rescues 
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the growth and differentiation defects of Sel1l-deficient pancreatic epithelium (Fig. 
2.6D and 2.6F).   
How does SEL1L negatively control Notch signaling in the developing 
mammalian pancreas is the focus of our current investigation. Genetic and 
biochemical evidences from other organisms such as Drosophila and C. elegans 
suggest that Notch signaling is regulated at multiple levels and through multiple 
mechanisms, including stochastical gene expression [34], selective ligand-receptor 
interactions [35], intracellular trafficking [37], and stability of NICD, the active form 
of Notch receptors [30]. Given the previous finding that mammalian NICD are 
ubiquitinated and degraded through both the proteasomal and lysosomal systems [55, 
56], it is conceivable that Sel1l may be directly or indirectly involved in control of 
NICD degradation. In this regard, it is noteworthy to mention that recent biochemical 
data from our laboratory indicate that NICD has significantly higher protein stability 
in Sel1l-deficient MEF cells (data not shown). Further proof of this hypothesis will 
require a detailed biochemical analysis of SEL1L and Notch interactions. 
In addition, biochemical evidences from other laboratories have underscored 
the importance of Sel1l in maintaining ER homeostasis. SEL1L interacts with the E3 
ubiquitin ligase HRD1 to facilitate the dislocation of unfolded or misfolded proteins 
from the ER lumen into the cytosol for degradation [48, 49, 57-60]. Consistent with 
this, we have recently shown that homozygous Sel1l mutant mice develop systemic 
ER stress. The impact of ER stress on pancreatic epithelial proliferation and 
differentiation remains undefined from the current study. However, several 
hypothetical roles of ER stress in pancreatic organ development and growth can be 
proposed. First, ER stress affects global gene expression. Upon ER stress, translation 
is generally down to reduce production of ER client proteins. Concomitantly, 
transcription of genes encoding ER chaperones and ER-associated degradation (ERAD) 
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machinery is increased. Second, ER stress blocks or reduces protein secretion by 
mammalian cells. This will directly affect cell signaling and cell functions. Finally, 
prolonged ER stress activates the signaling pathways leading to apoptosis. 
 
2.5 Conclusions 
We report that during mouse pancreatic development, Sel1l is preferentially 
expressed in the differentiating or differentiated pancreatic epithelial cells. Disruption 
of Sel1l function results in impaired endocrine lineage formation and delayed exocrine 
lineage differentiation. Pharmacological suppression of Notch signaling in cultured 
pancreatic explants partially rescues the endocrine cell differentiation defect. Our data 
suggest that Sel1l may regulate pancreatic epithelial growth and differentiation by 
suppressing Notch-mediated signaling. 
 
2.6 Methods 
Sel1l gene trap mice 
The chimeric founder mouse used to generate Sel1l gene trap mice was 
generated by microinjection of a commercially available mouse embryonic stem (ES) 
cell clone, CA0017, into C57/BL6 blastocysts. This ES cell clone contains a gene trap 
insertion in the 14th intron of the Sel1l gene. All mice or mouse embryos were 





All animal experiments were performed in accordance with the Cornell Animal 
Care and Use Guidelines. 
  41
Histology and immunohistochemistry 
Embryos or pancreatic rudiments were fixed in 4% paraformaldehyde (PFA) in 
PBS at 4°C for 12 hours or longer. PFA-fixed specimens were equilibrated in 30% 
sucrose in PBS at 4°C and embedded in O.C.T. Sections were cut at 10 μm and 
immunostained essentially as described [61, 62]. Briefly, tissue sections were 
permeabilized with 0.2% Triton X-100 in PBS for 20 min, washed 3 times in 0.1% 
Triton X-100 in PBS and 3 times in PBS. The permeabilized sections were pre-
incubated with 5% normal donkey serum and 1% BSA in PBS at room temperature for 
at least 1 hour, followed by incubation in the same solution with primary antibodies at 
4°C overnight. The antibody-bound sections were then washed three times in 0.1% 
Triton X-100 in PBS, 3 times in PBS and then incubated with secondary antibodies for 
1-3 hrs at room temperature. Primary antibodies were diluted in 1% BSA in PBS as 
follows: rabbit anti-b-Galactosidase (Immunology Consultants Laboratory), 1:500; 
guinea pig anti-Pdx-1 (Abcam), 1:1000; goat anti-Pdx1 (Abcam), 1:1000; guinea pig 
anti-insulin (Linco), 1:1000; rabbit anti-glucagon (Covance), 1:500; goat anti-
glucagon (AbD Serotec), 1:200; rabbit anti-Sox9 (gift from Dr. Michael Wegner), 
1:1000; rabbit anti-Ptf1a (gift from Dr. Helena Edlund), 1:1000); and rabbit anti-
amylase (Sigma), 1:500. Secondary antibodies were diluted in 1% BSA in PBS as 
follows: donkey anti-rabbit IgG conjugated to Cy3 (Jackson Immuno Research), 
1:1000; donkey anti-guinea pig IgG conjugated to Cy2 (Jackson Immuno Research), 
1:500. Fluorescence images were acquired using an Axiovert 40 microscope (Zeiss) 
equipped with an AxioCam camera. 
Pancreatic morphometry and cell counting 
Quantitative morphometry of the developing pancreas and cell counting were 
performed essentially as described [11]. Briefly, pancreata of age-matched wild-type 
and Sel1lβgeo/βgeo embryos were sectioned through and every fifth section was 
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immunostained with anti-PDX1 or co-immunostained with anti-PDX1 and anti-
Glucagon. Quantification of pancreatic epithelium area (PDX1+ area) was performed 
using AxioVision Imaging analysis software (version 4.6.3). The data were presented 
as averages ± SEM (μm2) of three independent pancreata. Statistical analysis was 
performed using the Student's two-sample t test and significance is regarded as p ≤ 
0.05. 
Pancreatic organ culture and DAPT treatment 
Sel1l+/βgeo mice were intercrossed to generate embryos of defined genotypes: 
wild-type (Sel1l+/+), heterozygous (Sel1l+/βgeo) and homozygous (Sel1lβgeo/βgeo). The day 
of the vaginal plug was taken as embryonic (E) day 0.5. Pancreatic bud dissection and 
culture were performed essentially as described [63]. Briefly, E11.5 embryos were 
decapitated and the dorsal pancreatic rudiment together with surrounding 
mesenchymal tissue was removed in PBS. The dissected pancreatic buds were rinsed 
once in culture medium, transferred to a fibronectin-coated 8-well LabTek chamber 
slide with the epithelial side touching the bottom of the slide and cultured for 72 hours 
in basal medium with Earle's salts (Gibco 21010-046), 1 × glutamine, 10% FBS and 
antibiotics. The cultured pancreatic rudiments were fixed individually for 30 minutes 
in 4% paraformaldehyde in PBS for immunohistological analysis. DAPT treatment of 
cultured pancreatic explants was performed essentially as described [64]. DAPT stock 
solution was prepared at a concentration of 10 mM in DMSO and was aliquoted into 
single-usage aliquots. For Notch inhibition experiments, pancreatic buds were cultured 
in complete medium containing 10 μM of DAPT. Control pancreatic buds were 
cultured in complete medium containing 0.1% DMSO. The DMSO or DAPT-treated 





We thank Dr. Patrick Biggs (Sanger Institute, UK) for generously providing 
the CA0017 mouse ES cell line; Drs. Raymond MacDonald (The University of Texas 
Southwestern Medical Center), Chyio Shiota and George Gittes (The University of 
Pittsburgh School of Medicine) for useful information about pancreatic explants 
culture; Drs. Yves Boisclair and Bruce Currie (Cornell University) for stimulating 
discussions and critical comments during preparation of the manuscript. The financial 
support for this research project was provided by the College of Agricultural and Life 




1. Slack JM. Developmental biology of the pancreas. Development. 121:1569–80. 
1995 
2. Jorgensen MC, Ahnfelt-Ronne J, Hald J, Madsen OD, Serup P, Hecksher-
Sorensen J. An illustrated review of early pancreas development in the mouse. 
Endocr Rev. 28:685–705. 2007 
3. Kim SK, MacDonald RJ. Signaling and transcriptional control of pancreatic 
organogenesis. Curr Opin Genet Dev. 12:540–7. 2002 
4. Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage 
NGN3+ cells are islet progenitors and are distinct from duct progenitors. 
Development. 129:2447–57. 2002 
5. Pictet RL, Clark WR, Williams RH, Rutter WJ. An ultrastructural analysis of the 
developing embryonic pancreas. Dev Biol. 29:436–67. 1972 
6. Ahlgren U, Jonsson J, Edlund H. The morphogenesis of the pancreatic 
mesenchyme is uncoupled from that of the pancreatic epithelium in IPF1/PDX1-
deficient mice. Development. 122:1409–16. 1996 
7. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan 
BL, Wright CV. PDX-1 is required for pancreatic outgrowth and differentiation 
of the rostral duodenum. Development. 122:983–95. 1996 
8. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. The 
role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic 
progenitors. Nat Genet. 32:128–34. 2002 
9. Krapp A, Knofler M, Frutiger S, Hughes GJ, Hagenbuchle O, Wellauer PK. The 
p48 DNA-binding subunit of transcription factor PTF1 is a new exocrine 
pancreas-specific basic helix-loop-helix protein. Embo J. 15:4317–29. 1996 
  45
10. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. Sox9 
coordinates a transcriptional network in pancreatic progenitor cells. Proc Natl 
Acad Sci USA. 104:10500–5. 2007 
11. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, Scherer G, 
Sander M. SOX9 is required for maintenance of the pancreatic progenitor cell 
pool. Proc Natl Acad Sci USA. 104:1865–70. 2007 
12. Gradwohl G, Dierich A, LeMeur M, Guillemot F. neurogenin3 is required for the 
development of the four endocrine cell lineages of the pancreas. Proc Natl Acad 
Sci USA. 97:1607–11. 2000 
13. Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de 
Angelis M, Lendahl U, Edlund H. Notch signalling controls pancreatic cell 
differentiation. Nature. 400:877–81. 1999 
14. Naya FJ, Huang HP, Qiu Y, Mutoh H, DeMayo FJ, Leiter AB, Tsai MJ. 
Diabetes defective pancreatic morphogenesis and abnormal enteroendocrine 
differentiation in BETA2/neuroD-deficient mice. Genes Dev. 11:2323–34. 1997 
15. Naya FJ, Stellrecht CM, Tsai MJ. Tissue-specific regulation of the insulin gene 
by a novel basic helix-loop-helix transcription factor. Genes Dev. 9:1009–19. 
1995 
16. Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. The Pax4 gene is 
essential for differentiation of insulin-producing beta cells in the mammalian 
pancreas. Nature. 386:399–402. 1997 
17. St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P. Pax6 is 
required for differentiation of glucagon-producing alpha-cells in mouse 
pancreas. Nature. 387:406–9. 1997 
18. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, 
Rubenstein JL, German MS. Mice lacking the homeodomain transcription factor 
  46
Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. 
Development. 125:2213–21. 1998 
19. Sander M, Sussel L, Conners J, Scheel D, Kalamaras J, Dela Cruz F, 
Schwitzgebel V, Hayes-Jordan A, German M. Homeobox gene Nkx6.1 lies 
downstream of Nkx2.2 in the major pathway of beta-cell formation in the 
pancreas. Development. 127:5533–40. 2000 
20. Collombat P, Mansouri A, Hecksher-Sorensen J, Serup P, Krull J, Gradwohl G, 
Gruss P. Opposing actions of Arx and Pax4 in endocrine pancreas development. 
Genes Dev. 17:2591–603. 2003 
21. Ahlgren U, Pfaff SL, Jessell TM, Edlund T, Edlund H. Independent requirement 
for ISL1 in formation of pancreatic mesenchyme and islet cells. Nature. 
385:257–60. 1997 
22. Gierl MS, Karoulias N, Wende H, Strehle M, Birchmeier C. The zinc-finger 
factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and 
intestinal endocrine cells. Genes Dev. 20:2465–78. 2006 
23. Johansson KA, Dursun U, Jordan N, Gu G, Beermann F, Gradwohl G, Grapin-
Botton A. Temporal control of neurogenin3 activity in pancreas progenitors 
reveals competence windows for the generation of different endocrine cell types. 
Dev Cell. 12:457–65. 2007 
24. Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, 
Guillemot F, Serup P, Madsen OD. Control of endodermal endocrine 
development by Hes-1. Nat Genet. 24:36–44. 2000 
25. Fujikura J, Hosoda K, Iwakura H, Tomita T, Noguchi M, Masuzaki H, Tanigaki 
K, Yabe D, Honjo T, Nakao K. Notch/Rbp-j signaling prevents premature 
endocrine and ductal cell differentiation in the pancreas. Cell Metab. 3:59–65. 
2006 
  47
26. Esni F, Ghosh B, Biankin AV, Lin JW, Albert MA, Yu X, MacDonald RJ, Civin 
CI, Real FX, Pack MA, Ball DW, Leach SD. Notch inhibits Ptf1 function and 
acinar cell differentiation in developing mouse and zebrafish pancreas. 
Development. 131:4213–24. 2004 
27. Hald J, Hjorth JP, German MS, Madsen OD, Serup P, Jensen J. Activated 
Notch1 prevents differentiation of pancreatic acinar cells and attenuate endocrine 
development. Dev Biol. 260:426–37. 2003 
28. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. Notch signaling controls 
multiple steps of pancreatic differentiation. Proc Natl Acad Sci USA. 
100:14920–5. 1998 
29. Greenwald I. LIN-12/Notch signaling: lessons from worms and flies. Genes Dev. 
12:1751–62. 2003 
30. Baron M, Aslam H, Flasza M, Fostier M, Higgs JE, Mazaleyrat SL, Wilkin MB. 
Multiple levels of Notch signal regulation (review). Mol Membr Biol. 19:27–38. 
2002 
31. Justice NJ, Jan YN. Variations on the Notch pathway in neural development. 
Curr Opin Neurobiol. 12:64–70. 2002 
32. Cormier S, Vandormael-Pournin S, Babinet C, Cohen-Tannoudji M. 
Developmental expression of the Notch signaling pathway genes during mouse 
preimplantation development. Gene Expr Patterns. 4:713–7. 2004 
33. Haddon C, Smithers L, Schneider-Maunoury S, Coche T, Henrique D, Lewis J. 
Multiple delta genes and lateral inhibition in zebrafish primary neurogenesis. 
Development. 125:359–70. 1998 
34. Kaern M, Elston TC, Blake WJ, Collins JJ. Stochasticity in gene expression: 
from theories to phenotypes. Nat Rev Genet. 6:451–64. 2005 
  48
35. Fleming RJ, Gu Y, Hukriede NA. Serrate-mediated activation of Notch is 
specifically blocked by the product of the gene fringe in the dorsal compartment 
of the Drosophila wing imaginal disc. Development. 124:2973–81. 1997 
36. Lawrence N, Klein T, Brennan K, Martinez Arias A. Structural requirements for 
notch signalling with delta and serrate during the development and patterning of 
the wing disc of Drosophila. Development. 127:3185–95. 2000 
37. Le Borgne R, Bardin A, Schweisguth F. The roles of receptor and ligand 
endocytosis in regulating Notch signaling. Development. 132:1751–62. 2005 
38. Lai EC. Protein degradation: four E3s for the notch pathway. Curr Biol. 12:R74–
8. 2002 
39. Biunno I, Castiglioni B, Rogozin IB, DeBellis G, Malferrari G, Cattaneo M. 
Cross-species conservation of SEL1L, a human pancreas-specific expressing 
gene. Omics. 6:187–98. 2002 
40. Biunno I, Appierto V, Cattaneo M, Leone BE, Balzano G, Socci C, Saccone S, 
Letizia A, Della Valle G, Sgaramella V. Isolation of a pancreas-specific gene 
located on human chromosome 14q31: expression analysis in human pancreatic 
ductal carcinomas. Genomics. 46:284–6. 1997 
41. Donoviel DB, Donoviel MS, Fan E, Hadjantonakis A, Bernstein A. Cloning and 
characterization of Sel-1l, a murine homolog of the C. elegans sel-1 gene. Mech 
Dev. 78:203–7. 1998 
42. Su AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Wiltshire T, Orth AP, Vega 
RG, Sapinoso LM, Moqrich A, Patapoutian A, Hampton GM, Schultz PG, 
Hogenesch JB. Large-scale analysis of the human and mouse transcriptomes. 
Proc Natl Acad Sci USA. 99:4465–70. 2002 
43. Donoviel DB, Bernstein A. SEL-1L maps to human chromosome 14, near the 
insulin-dependent diabetes mellitus locus 11. Genomics. 56:232–3. 1999 
  49
44. Sundaram M, Greenwald I. Suppressors of a lin-12 hypomorph define genes that 
interact with both lin-12 and glp-1 in Caenorhabditis elegans. Genetics. 
135:765–83. 1993 
45. Grant B, Greenwald I. The Caenorhabditis elegans sel-1 gene, a negative 
regulator of lin-12 and glp-1, encodes a predicted extracellular protein. Genetics. 
143:237–47. 1996 
46. Grant B, Greenwald I. Structure, function, and expression of SEL-1, a negative 
regulator of LIN-12 and GLP-1 in C. elegans. Development. 124:637–44. 1997 
47. Rooman I, De Medts N, Baeyens L, Lardon J, De Breuck S, Heimberg H, 
Bouwens L. Expression of the Notch signaling pathway and effect on exocrine 
cell proliferation in adult rat pancreas. Am J Pathol. 169:1206–14. 2006 
48. Hosokawa N, Wada I, Nagasawa K, Moriyama T, Okawa K, Nagata K. Human 
XTP3-B forms an endoplasmic reticulum quality control scaffold with the 
HRD1-SEL1L ubiquitin ligase complex and BiP. J Biol Chem. 283:20914–24. 
2008 
49. Mueller B, Lilley BN, Ploegh HL. SEL1L, the homologue of yeast Hrd3p, is 
involved in protein dislocation from the mammalian ER. J Cell Biol. 175:261–
70. 2006 
50. Zecchin E, Filippi A, Biemar F, Tiso N, Pauls S, Ellertsdottir E, Gnugge L, 
Bortolussi M, Driever W, Argenton F. Distinct delta and jagged genes control 
sequential segregation of pancreatic cell types from precursor pools in zebrafish. 
Dev Biol. 301:192–204. 2007 
51. Wessells NK, Evans J. Ultrastructural studies of early morphogenesis and 
cytodifferentiation in the embryonic mammalian pancreas. Dev Biol. 17:413–46. 
1968 
  50
52. Rall LB, Pictet RL, Williams RH, Rutter WJ. Early differentiation of glucagon-
producing cells in embryonic pancreas: a possible developmental role for 
glucagon. Proc Natl Acad Sci USA. 70:3478–82. 1973 
53. Sundaram M, Greenwald I. Genetic and phenotypic studies of hypomorphic lin-
12 mutants in Caenorhabditis elegans. Genetics. 135:755–63. 1993 
54. Chiaramonte R, Calzavara E, Basile A, Comi P, Sherbet GV. Notch signal 
transduction is not regulated by SEL1L in leukaemia and lymphoma cells in 
culture. Anticancer Res. 22:4211–4. 2002 
55. Mukherjee A, Veraksa A, Bauer A, Rosse C, Camonis J, Artavanis-Tsakonas S. 
Regulation of Notch signalling by non-visual beta-arrestin. Nat Cell Biol. 
7:1191–201. 2005 
56. Chastagner P, Israel A, Brou C. AIP4/Itch regulates Notch receptor degradation 
in the absence of ligand. PLoS ONE. 3:e2735. 2008 
57. Cattaneo M, Otsu M, Fagioli C, Martino S, Lotti LV, Sitia R, Biunno I. SEL1L 
and HRD1 are involved in the degradation of unassembled secretory Ig-mu 
chains. J Cell Physiol. 215:794–802. 2008 
58. Cormier JH, Tamura T, Sunryd JC, Hebert DN. EDEM1 recognition and 
delivery of misfolded proteins to the SEL1L-containing ERAD complex. Mol 
Cell. 34:627–33. 2009 
59. Mueller B, Klemm EJ, Spooner E, Claessen JH, Ploegh HL. SEL1L nucleates a 
protein complex required for dislocation of misfolded glycoproteins. Proc Natl 
Acad Sci USA. 105:12325–30. 2008 
60. Oresic K, Mueller B, Tortorella D. Cln6 mutants associated with neuronal ceroid 
lipofuscinosis are degraded in a proteasome-dependent manner. Biosci Rep. 
29:173–81. 2009 
  51
61. Burlison JS, Long Q, Fujitani Y, Wright CV, Magnuson MA. Pdx-1 and Ptf1a 
concurrently determine fate specification of pancreatic multipotent progenitor 
cells. Dev Biol. 316:74–86. 2008 
62. Matsuoka TA, Zhao L, Artner I, Jarrett HW, Friedman D, Means A, Stein R. 
Members of the large Maf transcription family regulate insulin gene transcription 
in islet beta cells. Mol Cell Biol. 23:6049–62. 2003 
63. Percival AC, Slack JM. Analysis of pancreatic development using a cell lineage 
label. Exp Cell Res. 247:123–32. 1999 
64. Cheng HT, Miner JH, Lin M, Tansey MG, Roth K, Kopan R. Gamma-secretase 
activity is dispensable for mesenchyme-to-epithelium transition but required for 
podocyte and proximal tubule formation in developing mouse kidney. 




RFX6 FUNCTIONS AS A TRANSCRIPTION REGULATOR FOR NKX6.1 IN 
PANCREATIC β CELLS 
 
3.1  Abstract  
Background: The vertebrate pancreas is comprised of endocrine, exocrine and 
ductal cells. These cells derive from a common pool of pancreatic progenitors during 
embryonic development. Understanding the genetic determinants underlying normal 
pancreatic development will accelerate the development of cell-based therapies for the 
treatment of diabetes mellitus.  
Methodology/Principal Findings: Through differential gene expression 
screening, we have identified a novel mouse gene, regulatory factor x 6 (Rfx6), with 
islet-specific expression.  We show here that the putative RFX6 protein contains a 
highly conserved winged helix-turn-helix DNA-binding domain (DBD). Ectopically 
expressed RFX6 is predominantly localized in the nucleus of mammalian cells. 
Knocking down of Rfx6 function using siRNA in the pancreatic β-cell line βTC3, 
causes down-regulation of Nkx6.1 mRNA expression, while ectopic expression of 
Rfx6 stimulates Nkx6.1 promoter activity. Zebrafish embryos injected with Rfx6-
specific morpholino antisense oligos exhibit attenuated insulin expression.   
Conclusions: Taken together, these results strongly suggest that RFX6 
functions as a transcriptional regulator for Nkx6.1 and may be involved in regulating 
β-cell differentiation and growth.  
  
3.2 Introduction  
The vertebrate pancreas contains acinar, ductal and islet cells.  These 
specialized cells derive from a transient pool of multipotent progenitor cells during 
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embryonic development [1].  In mice, pancreatic development begins at about 
embryonic day 8.5-9 (E8.5-9) with the formation two pancreatic epithelial buds.  
During the next several embryonic days (E9 to E12.5), the pancreatic epithelium 
grows and branches out to form a complex epithelial structure consisting of numerous 
elongated tubules [2, 3]. This period of epithelial growth creates a transient pool of 
pluripotent pancreatic progenitors that later differentiate to give rise to all the 
specialized cell types of the adult pancreas, including ducts, acini and islets [4, 5], 
which include glucagon-secreting α-cells, insulin- 
secreting β-cells, somatostatin-secreting δ-cells and pancreatic polypeptide-secreting 
pp¬cells [1].  
Early pancreatic epithelial cells express PDX1 [6, 7], SOX9 [8, 9] and PTF1a 
[5]. Genetic mutations in these genes impair early pancreatic epithelial expansion and 
morphogenesis and, therefore, prevent formation of the islets, acini and ducts of the 
pancreas. Mice lacking PDX1 have no pancreas; the pancreatic epithelium fails to 
grow and to undergo branching morphogenesis and there is no pancreatic formation 
[10-12]. The pancreatic epithelium of mice with targeted disruption of PTF1a grows 
poorly [13] and adopt the normal fate of duodenal epithelium [5]. SOX9 expression is 
restricted to the mitotically active multipotent pancreatic progenitors and pancreas-
specific inactivation of Sox9 results in premature differentiation of the pancreatic 
epithelial cells [8, 9]. These findings suggest that PDX1, PTF1a and SOX9 coordinate 
the induction and growth of the early pancreatic epithelium.  
During mouse pancreatic organogenesis, endocrine cells arise in two 
temporally distinct phases. The first sign of endocrine differentiation is the appearance 
of a small group of (mostly glucagon-expressing cells) endocrine cells in the primitive 
pancreatic epithelial buds from E9 to E12.5 (primary transition) [14, 15].  These early 
glucagon-expressing cells display a molecular profile that is distinct from mature 
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alpha cells [16] and do not contribute significantly to the mature endocrine mass [17, 
18]. Between E13.5 to E15.5, endocrine cells of all subtypes along with exocrine cells 
are produced in significant numbers (secondary transition) [19, 20].  Genetic 
inactivation of a single transcription factor, Neurogenin-3 (NGN3), abolishes the 
formation of all the endocrine cell types in mice [21].  Conversely, forced expression 
of NGN3 in early PDX1+ epithelial cells induces endocrine cell formation [22, 23]. 
Together, these results suggest that NGN3 is both essential and sufficient for initiation 
of endocrine cell differentiation in the developing pancreas.  
Significant efforts have been made to understand the roles of other 
transcriptional factors, including NeuroD1 [24, 25], Pax4 [26], Pax6 [27], Nkx2.2 [28], 
Nkx6.1 [29], Arx [30], Isl1 [31] and Insm1 [32]. It is now generally accepted that, 
during pancreatic organogenesis, a network of transcription factors coordinate 
pancreatic morphogenesis by functioning in concert to restrict the developmental 
potentials of the pancreatic progenitors in a spatial and stage-specific manner [20, 33-
36].     
The regulatory factor x (RFX) family of transcriptional factors comprises five 
structurally related members (RFX1-5) [37].  RFX proteins share a highly conserved 
76¬amino acid winged helix-turn-helix DNA binding domain (DBD). With the 
exception of RFX5, RFX proteins also contain three additional conserved regions: a 
dimerization domain (DMD), B and C domains [37]. RFX proteins can form homo- or 
heterodimers and regulate the expression of their target genes by binding to the 
symmetric X-box motif (5’-GTNRCC(0-3N)RGYAAC-3’, where N is any nucleotide, 
R is a purine and Y is a pyrimidine) in the promoter region [38].  The developmental 
and physiological roles of the Rfx genes have just begun to be recognized. Rfx3 is 
expressed in the ciliated cells of the node and targeted disruption of Rfx3 in mice 
causes left-right asymmetry defects [39].  Recently, it has been shown that Rfx3 
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deficiency also causes a significant reduction of beta cell mass and disorganization of 
the pancreatic islets [40].  Rfx4 is distantly related to Rfx3 and disruption of a brain-
specific isoform of RFX4 (RFX4_v3) causes fatal failure of dorsal midline brain 
structure formation [41].  The functions of RFX1, RFX2 and RFX5 remain elusive, 
but they have been implicated in regulating the expression of several genes involved in 
immune responses, such as interferon gamma and class II major histocompatability 
complex (MHC) genes [42-44].    
Rfx6 is a recently identified member of the mammalian Rfx gene family [45]. 
Among all the RFX proteins, RFX6 shows the highest sequence and structural 
homology to RFX4. Through differential gene expression screening, we have found 
that the mouse Rfx6 gene is preferentially expressed in the islet cells of the adult 
pancreas.  In this study, we have analyzed the sequence, expression and functions of 
RFX6.  Our findings indicate that RFX6 functions as a transcriptional activator for the 
endocrine lineage specific gene Nkx6.1. These data, together with the recently 
published mouse genetic data [46, 47], suggest that RFX6 is an important regulator for 
the development and function of the mammalian endocrine pancreas.  
 
3.3 Results  
Identification of the mouse Rfx6 gene  
In an attempt to identify novel factors with enriched expression in pancreatic 
islets, we screened 30 candidate genes using semi-quantitative RT-PCR.  These genes 
were selected based on their expressed sequence tag (EST) profiles in the Unigene 
database [48]. One of the genes found to be preferentially expressed in the mouse 
pancreatic islets was previously named Rfxdc1 (for regulatory factor X domain-
containing 1). Recently, Rfxdc1 has been re-named as Rfx6 (for regulatory factor X 6, 
GeneID#: 320995) based on its significant sequence homology with other members of 
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the RFX family of regulatory proteins [45]. Twenty four Rfx6-related mouse 
expressed sequence tags (EST) are currently registered in the GenBank database.  
These EST sequences predict at least two Rfx6 transcripts: Rfx6-v1 (NM_001159389) 
and Rfx6-v2 (NM_177306).  The longest Rfx6 mRNA has a putative ORF of 2793 
nucleotides which encodes a peptide of 893 amino acids (Accession # FJ804414). The 
deduced peptide shows 87.4, 78.8 and 65.2 percent sequence identity to the predicted 
human, chicken and zebrafish RFX6, respectively. The N-terminal half of the RFX6 
sequence is highly conserved among human, mouse and zebrafish.  The conserved 
region contains a winged helix-turn-helix DNA-binding domain (DBD), a 
dimerization domain (DMD) and two other domains, B- and C-domains (Fig.1, green, 
blue, pink and yellow box, respectively).  These domains are found in members of the 
RFX family of transcriptional factors [45].  RFX6 shows 28.5, 29.2, 27.8, 36.6 and 
12.7 percent sequence identity to RFX1 (NM_009055), RFX2 (NM_009056), RFX3 
(NM_011265), RFX4 (NM_001024918) and RFX5 (NM_017395), respectively.  
Predictions of protein sorting and other sequence motifs using the online PSORT 
software [49] failed to reveal any nuclear localization signal in RFX6, but identified 7 
highly conserved dileucine motifs within the C- and DMD-domains (Fig. 3.1, 
highlighted in red).  
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Figure 3.1 RFX6 sequence is highly conserved among vertebrate species. Human, 
mouse and zebrafish RFX6 sequences (BC039248, FJ804414 and XM_679861, 
respectively) were aligned using the Lasergene Megalign program.  Note that the N-
terminal half of the RFX6 sequence is highly conserved among human, mouse and 
zebrafish. The conserved region contains a winged helix DNA-binding (green), B- 
(blue), C- (pink) and dimerization (yellow) domains.  Seven conserved dileucine 
motifs are found in RFX6 (highlighted in red). 
 
The mouse Rfx6 gene is preferentially expressed in the developing and matured 
pancreatic islets  
According to the gene expression data available from UniGene 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.109190) 
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and UCSC Mouse Gene Sorter (http://genome.ucsc.edu/cgi¬bin/hgNear?hgsid=15047 
8630&org=Mouse&db=mm9&near_search=rfxdc1&submit=Go%21&near_order=exp
GnfAtlas2&near.count=100), Rfx6 is preferentially expressed in the endocrine 
compartment of the pancreas.  To assess the tissue distribution of Rfx6 transcripts in 
adult mice, we isolated total RNAs from brain, liver, lung, kidney, skeletal muscle, 
heart, whole pancreas and islets of 6 week old female mice and performed quantitative 
RT-PCR analysis. As shown in Fig. 3.2A, Rfx6 transcripts were detected exclusively 
in the islets of Langerhans of the pancreas.  To assess the expression of the mouse 
Rfx6 gene during pancreatic development, we isolated total RNA from the dorsal 
pancreatic bud and two adjacent tissues, stomach and spleen rudiments, from E14.5-
15.5 embryos and performed semi-quantitative RT-PCR analysis.  Significantly higher 
Rfx6 mRNA was detected in the dorsal pancreatic bud than in the stomach and spleen 
rudiments [Fig. 3.2B]. Together, these results indicate that the mouse Rfx6 gene is 
preferentially expressed in the developing pancreas and in the endocrine lineage of the 
matured pancreas in mice.   
 
RFX6 is preferentially localized in the nucleus of mammalian cells   
The predicted RFX6 peptide sequence contains a winged helix DNA-binding 
domain but has no obvious nuclear localization signal.  Previous studies showed that 
RFX1-5 functions as transcriptional regulators in various embryonic and adult tissues. 
To determine whether RFX6 is nuclear factor, we assessed the sub-cellular 
localization of RFX6 protein. For this study, Hela cells were transfected with an 
expression plasmid encoding a FLAG-tagged RFX6. The transfected cells were 
immunostained with an anti-FLAG antibody. Of the transfected Hela cells, 55.3% 
exhibit FLAG-RFX6 in the nucleus (Fig. 3.3A and D), 26.3% contain FLAG-RFX6 in 
the nucleus (Fig. 3.3B and D) and the remainder cells show FLAG-RFX6 in both the 
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nucleus and the cytoplasm (Fig. 3.3C). Thus, ectopically expressed RFX6 is 
preferentially localized in the nucleus of mammalian cells.  Given the fact that RFX6 
contains a highly conserved winged-helix DNA-binding domain, these results suggest 
that RFX6 may function as a transcriptional regulator.   
 
 
Figure 3.2 Rfx6 mRNA is highly expressed in the developing and matured 
pancreas and in islets of Langerhans of the pancreas. (A) Quantitative RT-PCR of 
Rfx6 mRNA expression in adult tissues.  Tissue-specific RNAs were isolated from 6 
week old female mice using Trizol.  Rfx6 mRNA expression was analyzed by 
quantitative RT-PCR.  The mRNA expression of 18S was used as an internal control 
to normalize Rfx6 expression as described in Materials & Methods.  The value of 
Rfx6 mRNA expression in skeletal muscle was set to 1 and used to calculate relative 
expression in other tissues. The data were expressed as means + S.D.  Statistical 
analysis was performed using the Student’s t-test and p < 0.05 is considered 
significantly different. (B) Semi-quantitative RT-PCR analysis of Rfx6 mRNA 
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expression in islets of Langerhans, whole pancreas, pancreatic, stomach and spleen 
rudiments.  Whole pancreas and islets of Langerhans were isolated from 6 week old 
female mice.  Dorsal pancreatic buds, stomach and spleen rudiments were dissected 
from E13.5-15.5 wild-type mouse embryos. Total RNAs were isolated from pooled 
pancreas, stomach and spleen rudiments and Rfx6 mRNA expression was analyzed by 
RT-PCR. Gapdh mRNA expression across the tissues was used as an internal control 
to ensure the use of equal amount of starting RNA.  
 
 
Figure 3.3 RFX6 is exclusively localized in the cytoplasm (A-C) Representative 
images of immunostained Hela cells ectopically expressing RFX6. Hela cells were 
transfected with an expression plasmid encoding Flag-tagged RFX6. Twenty four hour 
after transfection, Hela cells were briefly fixed in 4% PFA and immunostained with an 
anti-FLAG antibody (Red).  Nuclei were stained with DAPI (blue).  RFX6-FLAG 
fusion protein is observed in the cytoplasm (A), nucleus (B) or both compartments (C). 
(D) Quantification of the percentage of cells with cytoplasmic, nucleus and mixed 
localizations.  Scale bars: 50 μm. 
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RFX6 functions as a transcriptional regulator for the endocrine lineage specific 
gene  Nkx6.1  
Previous studies have identified and characterized more than a dozen of 
endocrine lineage-specific transcription factors.  These factors are involved in control 
of insulin gene expression, β-cell function and growth. To assess whether RFX6 plays 
any role in adult β cells, we performed siRNA-mediated functional knocking-down 
studies in the mouse pancreatic beta cell line, βTC3 [50].  Control (lacZ) and Rfx6-
specific siRNAs were transfected into βTC3 cells.  Subsequently, total RNAs were 
isolated from the transfected βTC3 cells and analyzed by semi-quantitative RT-PCR. 
Semi-quantitative RT-PCR analysis showed that transfection of Rfx6 siRNA, not 
LacZ siRNA, caused a significant decrease of Rfx6 mRNA level in βTC3 cells (Fig. 
3.4A).  This suggests that the synthetic Rfx6 siRNA specifically targeted endogenous 
Rfx6 mRNA for degradation.  To assess whether knocking-down of RFX6 affects 
pancreatic gene expression, we analyzed the mRNA expression of 12 islet-specific 
transcription factors, including Beta2, Hes1, Isl1, IA1, MafA, Ngn3, Pax6, Nkx2.1, 
Nkx6.1, Pax4, Pax6 and Pdx1. No significant alteration of Beta2, Hes1, Isl1, IA1, 
MafA, Ngn3, Nkx2.1, Pax4, Pax6 and Pdx1 expression was detected between LacZ 
and Rfx6 siRNA transfected cells (data not shown). However, Nkx6.1 expression was 
down-regulated nearly 2 folds in Rfx6-siRNA transfected βTC3 cells (Fig. 3.4B). 
Based on these observations, we speculated that RFX6 may be directly or indirectly 
involved in the transcriptional regulation of Nkx6.1 in pancreatic β cells. To test this 
hypothesis, we generated a luciferase reporter construct containing 1.3-kb of the 5’ 
flanking region of the mouse Nkx6.1 gene. This proximal promoter region of Nkx6.1 
was previously shown to contain a β-cell specific enhancer [51]. As a control, we also 
generated a luciferase reporter construct containing 1.8-kb of the 5’ flanking region of 
the mouse Rfx6 gene. We then co-transfected the luciferase reporter constructs with an 
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expression plasmid encoding either GFP or RFX6 into HEK293 (non-β) and Min6 (β) 
cells.  Luciferase analysis showed that, in both β and non¬β cell lines, ectopic 
expression of RFX6 markedly activates the Nkx6.1, but not the Rfx6 proximal 
promoter (Fig. 3.4C-D).  These results, together with the siRNA knocking-down data, 
strongly indicate that RFX6 functions as a transcriptional activator for the endocrine 
lineage specific gene Nkx6.1 in matured pancreatic β cells.  
 
 
Figure 3.4 RFX6 functions as a transcriptional regulator for the endocrine 
lineage-specific gene Nkx6.1. (Α) Semi-quantitative RT-PCR analysis of Rfx6 
mRNA expression in βTC3 cells transfected with lacZ and Rfx6 specific siRNAs. 
Note that Rfx6 mRNA level was significantly decreased in Rfx6-specific siRNA 
transfected βTC3 cells, suggesting Rfx6 siRNA specifically targeted Rfx6 mRNA for 
degradation. (B) Quantitative RT-PCR analysis of Nkx6.1 mRNA expression in LacZ 
and Rfx6 specific siRNA-treated βTC3 cells. The value of Nkx6.1 mRNA expression 
in Rfx6 siRNA-treated βTC3 was set to 1 and used to calculate relative expression 
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level in LacZ siRNA-treated βTC3 cells. N = 3 independent transfections, *, p < 0.05, 
**, p < 0.01 LacZ versus Rfx6 siRNA-treated βTC3 cells. (C-D) Quantitative analyses 
of Rfx6 and Nkx6.1 promoter (pRfx6 and pNkx6.1) activities in Min6 (C) and 
HEK293 (D) cells transiently expressing GFP or RFX6. Min6 and HEK293 cells were 
transiently co-transfected with expression plasmids encoding either GFP or RFX6 
with luciferase reporter constructs containing either the mouse Rfx6 or Nkx6.1 gene 
proximal promoter.  An expression plasmid encoding β¬galactosidase (βgal) was 
included in all transfection and was used as internal control to normalize transfection 
efficiency among different groups.  Luciferase assay was performed 24 hours after 
transfection.  N = 3 independent transfections, *, p < 0.05, ** , p < 0.01 GFP versus 
RFX6-expressing cells.  
 
Rfx6 is required for islet formation during zebrafish embryonic development  
To assess the role of Rfx6 in control of pancreatic development, we made use 
of the zebrafish model. RNA in situ hybridization was used to analyze the spatial-
temporal expression of the zebrafish Rfx6 gene. Rfx6 transcripts were detected at the 
pharyngula stage (36 hours post fertilization, hpf) in the pancreatic epithelium (Fig. 
3.5A, arrow). To assess the role of Rfx6 in regulating zebrafish pancreatic 
development, LacZ- (control) and Rfx6-specific morpholino antisense 
oligonucleotides (MO) were injected into one-cell stage zebrafish embryos.  Injection 
of Rfx6-specific MO caused a significant decrease of Rfx6 mRNA in zebrafish 
embryos as compared to LacZ MO injected embryos (Fig. 3.5B), suggesting that the 
Rfx6-specific MO specifically targeted Rfx6 mRNA for degradation. MO injected 
embryos were allowed to develop for 36 hours and then subjected to RNA in situ 
hybridization using a digoxygenin-labeled insulin antisense riboprobe. At 36 hpf, Rfx6 
MO-injected embryos showed either a decreased insulin expression (Fig. 3.5D and G) 
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or a disorganized islet (Fig. 3.5G and 3.5H), compared to control MO injected 
embryos (Fig. 3.5C and F).  The observed pancreatic phenotypes correlated positively 
with the dose of the MO and, importantly, were rescued by co-injection of the 
morpholino oligonucleotides with Rfx6 synthetic mRNA (Fig. 3.5I).  We quantified 
the expression of insulin mRNA in control and Rfx6-spefic MO injected embryos 
using real-time RT-PCR.  Insulin expression was significantly decreased by the 
injection of Rfx6 MO (Fig. 3.5J). Together, these data suggest that RFX6 is critical for 
beta cell differentiation and islet formation during zebrafish pancreatic development.  
 
Figure 3.5 Knocking-down of RFX6 function in zebrafish impairs β-cell 
development and insulin expression.  (A) RNA in situ hybridization of zebrafish 
embryos at the pharyngula stage using an antisense zebrafish Rfx6 probe. Rfx6 mRNA 
was detected in the pancreatic primordial (arrow). (B) Semi-quantitative RT-PCR 
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analysis of LacZ (lane 1) and Rfx6-specific (lane 2 and 3) morpholino (MO) oligos 
injected  embryos.  Injection of Rfx6-specific morpholino oligonucleotides results in 
decreased levels of Rfx6 mRNA in zebrafish embryos. (C-E) RNA in situ analysis of 
insulin mRNA expression in LacZ (C) and Rfx6 (D-E) MO injected zebrafish embryos. 
LacZ MO injected embryos had reduced insulin expression (D) or impaired islet 
morphology (E). (F-H) Magnified views of the boxed areas in C-E, respectively. (I) 
Quantification of zebrafish embryos with pancreatic defects. (J) Quantitative RT-PCR 
analysis of insulin mRNA expression in uninjected (UI), LacZ and Rfx6 MO injected 
embryos. N = 3 independent injections, *, p < 0.05 Rfx6 versus LacZ MO injected 
embryos.   
 
3.4 Discussion  
The endocrine and exocrine lineages of the pancreas derive from a transient 
pool of pancreatic progenitors during embryonic development. The genetic 
determinants underlying endocrine pancreas formation, function and survival are not 
completely understood. Through differential gene expression screening, we have 
identified a novel mouse gene, Rfx6. We show here that Rfx6 encodes a nuclear 
protein with a winged-helix DNA-binding domain. Rfx6 is exclusively expressed in 
the islets of Langerhans of the pancreas in adult mice. Knocking-down of Rfx6 
function in pancreatic β cells using siRNA causes significant down-regulation of 
Nkx6.1 mRNA expression.  Consistent with this, ectopic expression of Rfx6 in both 
non-β and β cells activates the Nkx6.1 proximal promoter. Rfx6 is expressed in the 
developing zebrafish pancreas at the pharyngula stage. Morpholino antisense oligo-
mediated knocking-down of Rfx6 function attenuates the differentiation of insulin-
expressing cells and impairs islet morphology.  Taken together, these results strongly 
suggest that RFX6 functions as a transcriptional activator for the islet-specific gene 
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Nkx6.1 in adult β cells. Our data also indicate that RFX6 may be an important 
regulator of islet cell formation during vertebrate embryonic development.  
Members of the RFX family share a highly conserved 76-amino acid winged 
helix DNA binding domain [45].  This domain binds to the X-box motifs in the 
regulatory region of target genes [38, 52].  We show by sequence alignment analysis 
that the deduced RFX6 peptide shows the highest sequence homology (36.6%) to 
RFX4. This suggests that Rfx6 may be derived from Rfx4 through a gene-duplication 
event during evolution. Sequence analysis also shows that, unlike other RFX proteins, 
RFX6 contains 7 dileucine motifs (Fig. 3.1). Of these 7 dileucine motifs, three are the 
“DxxxLL” type that has previously been implicated in interactions with the 
heterotetramer assembly protein 2 (AP-2) adaptor protein complex of the clathrin-
coated vesicles (CCV) [53]. “DxxxLL” type dileucine motifs have been found in many 
membrane receptors and their ligands and is used by the cellular sorting machinery as 
an internalization signal [54, 55].  We have demonstrated, through ectopic expression 
of RFX6 in Hela cells, that RFX6 is predominantly localized in the nucleus of 
mammalian cells.  More importantly, we show that siRNA-mediated knocking-down 
of RFX6 causes significant down-regulation of Nkx6.1 gene expression. Furthermore, 
ectopic expression of RFX6 activates the Nkx6.1 gene proximal promoter.  Together, 
these data suggest that RFX6, as other members of the RFX protein family, functions 
as a transcription factor.  It is important to point out, however, that it is possible that a 
small amount of RFX6 may be localized in the cytoplasm and thus may play a role in 
intracellular protein sorting.  Further molecular and biochemical studies are needed to 
define the role of the multiple dileucine motifs in RFX6.  
Rfx6 mRNA is exclusively expressed in the islets of Langerhans of the 
pancreas. Through siRNA-mediated functional knocking-down and promoter reporter 
assays in βTC3 cells, we demonstrate convincingly, that RFX6 positively regulates the 
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transcription of the mouse Nkx6.1 gene. Previous studies have shown that the 
homeobox gene Nkx6.1 plays an essential role in regulating the differentiation of the 
endocrine lineage of the pancreas during mouse embryonic development.  Targeted 
disruption of Nkx6.1 in mice leads to loss of β-cell precursors and blocks β-cell 
differentiation during the secondary transition [29].  More recently, it has been shown 
that over-expression of Nkx6.1 in both human and rat islets stimulate β-cell replication 
with retention or enhancement of β-cell function, suggesting that Nkx6.1 is critically 
required for β-cell growth in adult mice [56].  Given the clear involvement of Nkx6.1 
in control of β-cell replication, we speculate that RFX6 may play an important role in 
regulating β-cell mass in adult mice.  Proof of this hypothesis will require genetic and 
molecular studies in mice.  
In conclusion, we have identified a novel islet-specific factor, RFX6, in mice. 
Here, we provide several lines of experimental evidence suggesting that RFX6 
functions as a transcriptional regulator for the homeobox gene Nkx6.1. While this 
manuscript was in review, two papers describing the expression and function of RFX6 
during vertebrate pancreas development were published [46, 47].  Our findings, 
together with the recently reported functional data on RFX6, have important 
implications in understanding the molecular mechanisms regulating β-cell 
development and growth in vertebrates.    
 
3.5 Materials and Methods  
Ethics Statement  
All mouse work was performed under approved Cornell University Animal 
Protocol # 2006-0087. All zebrafish work was performed under approved Medical 
College of Wisconsin Animal Protocol # 312-06-2.  
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DNA Constructs and luciferase assay  
Two promoter constructs tethered to a luciferase reporter gene were used: 
pRfx6-Luc and pNkx6.1-Luc. To generate pRfx-Luc, the 5’ flanking region of the 
mouse Rfx6 gene (¬1837 to +1) was amplified by PCR using the following primers: 
5’¬GCTCTTACGCGTGCCCCTGTAGAGTAGGTTATC-3’(forward) and 5’- 
GATCGCAGATCTCCTTCCCACCGCCCGGAT-3’ (reverse).  The PCR-amplified 
Rfx6 promoter fragment was cut with Mlu I and Bgl II and the resulting fragment was 
subcloned between the Mlu I and Bgl II sites of the pGL3-Basic luciferase vector 
(Promega, Madison, WI).  To generate pNkx6.1-Luc, the 5’ flanking region of the 
mouse Nkx6.1 gene (-1317 to +1) was amplified by PCR using the following primers: 
5’- ACGCGTGCTGGCTCTAGACTGGAA -3’ (forward) and 
5’¬GGATCCCCCACAGCCAGACCCGAA-3’ (reverse).  The PCR-amplified 
Nkx6.1 promoter fragment was first cloned into pGEM-T vector (Promega, Madison, 
WI).  The Nkx6.1 promoter fragment was then released from pGEM-T vector by Mlu 
I and Bam HI double digestion and subcloned between the Mlu I and Bgl II sites of 
pGL3-Basic luciferase vector. The RFX6-Flag expression construct, pRfx6-Flag, was 
generated through the following steps: First, pDNR-CMV-Flag vector was modified 
from pDNR¬CMV vector (Clontech, Mountain View, CA) by creating an adaptor 
using two synthetic oligonucleotides: 5’-AGCTTGACTACAAAGACGAT 
GACGACAAGTGAG-3’ (forward) and 5’-CGCGCTCACTTGTCGTCATCGTCTTT 
GTAGTCA-3’ (reverse). Subsequently, the open reading frame region of the mouse 
Rfx6 cDNA was amplified by PCR using the following primers: 5’-
TTGAATTCCGCCACCATGGCTAAG GTCCGGGAA -3’ (forward) and 5’- 
TTCTCGAGAGTGTCTCCAGCTGCTGT -3’ (reverse). The PCR products were cut 
with Eco RI and Xho I and the resulting fragments were subcloned between the Eco 
RI and Xho I sites of pDNR-CMV-cFLAG vector. All plasmid constructs were 
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confirmed by restriction enzyme digestion and sequencing. For luciferase assay, 
HEK293 or Min6 cells were transfected using polyethylenimine (PEI) (Sigma) with 
3.5 μg of DNA mix containing 0.5, 1 and 2 μg of pCMV-βgal (transfection control), 
different luciferease reporter construct and pRfx6¬Flag or pEGFP-N2, respectively.  
Islet Isolation  
Mouse islet isolation was performed using collagenase digestion and Ficoll 
gradient centrifugation as previously described (57). Briefly, after anesthetizing each 
mouse, the pancreas was perfused with 1 x Hank’ Balanced Salt Solution (HBSS) 
(pH7.4) containing 2.0 mg/ml of type V collagenase (Sigma).  The inflated pancreas 
was dissected and incubated at 37oC for 20 minutes.  The collagenase-digested 
pancreas was vigorously shaken for 5 seconds to release islets from acinar tissues, 
washed three times with 5-7 mls of ice-cold 1 x HBSS buffer and re-suspended in 2 
mls of 28% Ficoll (VWR).  The islet and acinar mixture was loaded onto the top of a 
gradient Ficoll solution as previously described and centrifuged at 2250 rpm for 7 
minutes at 4oC.  Islets were collected and washed three times with cold 1 x HBSS and 
processed for further analysis.   
RNA isolation and quantitative RT-PCR  
RNA isolation was performed using the TRIZOL RNA Isolation Kit 
(Invitrogen, Carlsbad, CA).  For quantitative RT-PCR analysis, the tissue-specific 
RNAs were treated with DNase I for 10 minutes and purified using the RNAqueous-
Micro Kit (Ambion, Austin, TX). First-strand cDNA was synthesized using 
SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA). Quantitative PCR 
was performed using Power SYBR Green PCR Master Mix on an ABI Prism 7000 
Sequence Detection System (Applied Biosystems).  Briefly, 25 ng of total cDNA was 
mixed with Power SYBR Green PCR Master solution (Applied Biosystems) in a 25 μl 
reaction. Quantification and normalization of mRNA expression was performed 
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essentially as described (58). Expression difference between compared groups was 
statistically analyzed by performing Student’s t-tests using the normalized mean value  
Transfection and immunohistological analysis of Hela cells  
Hela cell transfection was done using polyethylenimine (PEI) (Sigma).  Hela 
cells were seeded at a density of 0.5 x 106 cells per well in 6-well dishes with cover 
slips.  After an overnight rest, Hela cells were rinsed twice with PBS, once with Opti-
MEM reduced serum medium (Invitrogen) and incubated for 12-16 hours with 1 ml of 
Opti-MEM reduced serum medium containing 3 μg of expression plasmid encoding 
RFX6-FLAG and 2 μl of PEI. Transfected Hela cells were fixed in 4% 
paraformaldehyde (PFA) in PBS at 4°C for over 2 hours. Immunostaining was 
performed essentially as described (59, 60). Briefly, Hela cells were permeabilized 
with 0.2% Triton X-100 in PBS for 20 min, washed 3 times in 0.1% Triton X-100 in 
PBS and 3 times in PBS.  The permeabilized sections were preincubated with 5% 
normal donkey serum and 1% BSA in PBS at room temperature for at least 1 hour, 
followed by incubation in the same solution with a mouse monoclonal anti-FLAG 
antibody (Sigma, 1:1000) at 4°C overnight.  The antibody-bound sections were 
washed three times in 0.1% Triton X-100 in PBS, 3 times in PBS alone and then 
incubated with Cy3-conjugated donkey anti-mouse secondary antibody (Jackson 
ImmunoResearch Laboratories, 1:500) for 1–3 hrs at room temperature. After 
extensive washing, fluorescence images were acquired using an Axiovert 40 
microscope (Zeiss) equipped with an AxioCam camera.  
Culture of βTC3 cells and siRNA transfection  
βTC3 cells were grown under conditions described previously (50).  The 
mouse Rfx6 coding region corresponding from +45 bp to +501 bp was amplified using 
the following primers: forward: TCTGCACCCATTCTCAACTG and reverse: 
CTCTTGTGTGTGTGTGGATGG. Control (lacZ) and Rfx6-specific siRNA were 
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generated using the BLOCK-iTTM Complete Dicer RNAi Kit (Invitrogen) according 
to the manufacturer’s recommendations. βTC3 cells were grown to 80% confluence 
and transfected with 100 ng of either lacZ- or Rfx6-specific siRNA per plate using 
LipofectamineTM 2000.  
Zebrafish studies     
All zebrafish work was performed under approved Medical College of 
Wisconsin Animal Protocol # 312-06-2. Antisense and sense digoxygenin-labeled 
riboprobes were synthesized using Sp6 and T7 RNA polymerase, respectively using 
template plasmid linearized with SacII and SalI, respectively. In situ hybridization 
using antisense Rfx6 digoxygenin-labeled RNA probe was performed as described 
previously (61). The Rfx6¬specific (5’-AATAAAAACGCCTCTTACCTTTCCG) and 
standard control (5’¬CCTCTTACCTCAGTTACAATTTATA) morpholino oligos 
were designed by GeneTools Inc. Morpholino (5-10 ng) and RNA (100-300 pg) 
injections were performed essentially as described (61). Primers used for detecting 
Rfx6 MO efficacy include: F: GCAAGCATCTCCTCTGAAGAGA, and R: 
CACTGCTCTCCTTGATTCCAATA. Zebrafish Actin primers were described 
previously (61). Capped mouse sense RNA was generated with SP6 polymerase from 
a NotI  linearized pCS2.1 template containing Rfx6 gene using the Ambion 
mMESSAGE kit. For rescue experiments, 10 ng of MO and 200 pg of capped sense 
mouse Rfx6 RNA was co-injected per embryo. Insulin mRNA expression was 
analyzed by quantitative RT-PCR using the following primers:  insulin-F: 5’-
AGTGTAAGCACTAACCCAGGCACA; insulin-R: 5’¬TGCAAAGTCAGCCACC 
TCAGTTTC.   
Statistical analysis  
Differences between groups were evaluated by performing two-tailed 
Student’s t-test and p < 0.05 is considered significant.  
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